

Altaf Mohammed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687980/publications.pdf>

Version: 2024-02-01

58
papers

1,757
citations

236925

25
h-index

289244

40
g-index

58
all docs

58
docs citations

58
times ranked

3033
citing authors

#	ARTICLE	IF	CITATIONS
1	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. Journal of Cancer Prevention, 2021, 26, 71-82.	2.0	4
2	Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice. Neoplasia, 2021, 23, 574-583.	5.3	9
3	Proton Pump Inhibitor Omeprazole Suppresses Carcinogen-induced Colonic Adenoma Progression to Adenocarcinoma in F344 Rat. Cancer Prevention Research, 2021, 14, 1009-1020.	1.5	5
4	Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). Cancer Prevention Research, 2021, 14, 325-336.	1.5	12
5	Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. Journal of Cancer Prevention, 2021, 26, 309-317.	2.0	1
6	Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. Cancer Prevention Research, 2020, 13, 273-282.	1.5	6
7	Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors. Cancer Prevention Research, 2020, 13, 897-900.	1.5	3
8	Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model. Cancer Prevention Research, 2020, 13, 185-194.	1.5	6
9	Targeting cholecystokinin ϵ 2 receptor for pancreatic cancer chemoprevention. Molecular Carcinogenesis, 2019, 58, 1908-1918.	2.7	6
10	Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. Cancer Prevention Research, 2019, 12, 751-762.	1.5	11
11	Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities. Toxicological Sciences, 2019, 170, 251-259.	3.1	9
12	Pancreatic Cancer Chemoprevention: Challenges and Opportunities. Current Medicinal Chemistry, 2018, 25, 2532-2534.	2.4	3
13	Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. Current Medicinal Chemistry, 2018, 25, 2535-2544.	2.4	8
14	Immunoprevention of Pancreatic Cancer. Current Medicinal Chemistry, 2018, 25, 2576-2584.	2.4	3
15	Molecular Pathways: Mucins and Drug Delivery in Cancer. Clinical Cancer Research, 2017, 23, 1373-1378.	7.0	40
16	Loss of natural killer T cells promotes pancreatic cancer in $LSL^{Kras^{G12D/+}}$ mice. Immunology, 2017, 152, 36-51.	4.4	57
17	Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage <i>in vivo</i> . Oncotarget, 2017, 8, 57605-57621.	1.8	55
18	Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget, 2017, 8, 97822-97834.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Prevention and treatment of cancers by immune modulating nutrients. <i>Molecular Nutrition and Food Research</i> , 2016, 60, 1275-1294.	3.3	30
20	Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer. <i>Scientific Reports</i> , 2016, 6, 37046.	3.3	22
21	(Z)-3,5,4-trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression. <i>Cancer Research</i> , 2016, 76, 4887-4896.	0.9	28
22	Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer. <i>Cancer Research</i> , 2016, 76, 1965-1974.	0.9	34
23	Systemic Chromosome Instability Resulted in Colonic Transcriptomic Changes in Metabolic, Proliferation, and Stem Cell Regulators in <i>Sgo1</i> Mice. <i>Cancer Research</i> , 2016, 76, 630-642.	0.9	17
24	Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer <i>In Vivo</i> . <i>Cancer Prevention Research</i> , 2016, 9, 53-62.	1.5	14
25	Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein. <i>Molecular Carcinogenesis</i> , 2015, 54, 986-998.	2.7	15
26	Sea Cucumbers Metabolites as Potent Anti-Cancer Agents. <i>Marine Drugs</i> , 2015, 13, 2909-2923.	4.6	91
27	New insights into pancreatic cancer stem cells. <i>World Journal of Stem Cells</i> , 2015, 7, 547.	2.8	54
28	Early and delayed intervention with Rapamycin prevents NNN-induced lung adenocarcinoma in A/J mice. <i>Oncology Reports</i> , 2015, 34, 2925-2934.	2.6	12
29	Improved Innate Immune Responses by Frondanol A5, a Sea Cucumber Extract, Prevent Intestinal Tumorigenesis. <i>Cancer Prevention Research</i> , 2015, 8, 327-337.	1.5	21
30	Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in <i>Sgo1</i> (Shugoshin 1) haploinsufficient mice. <i>Carcinogenesis</i> , 2015, 36, 429-440.	2.8	20
31	Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. <i>Oncotarget</i> , 2015, 6, 15524-15539.	1.8	38
32	Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 33290-33305.	1.8	29
33	Molecular Targeted Intervention for Pancreatic Cancer. <i>Cancers</i> , 2015, 7, 1499-1542.	3.7	30
34	Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells. <i>Cancer Prevention Research</i> , 2014, 7, 300-309.	1.5	9
35	Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APC ^{min/+} Mouse Intestinal Tumorigenesis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 59-68.	2.5	13
36	Chemoprevention of Urothelial Cell Carcinoma Growth and Invasion by the Dual COX-2/LOX Inhibitor Licofelone in UPII-SV40T Transgenic Mice. <i>Cancer Prevention Research</i> , 2014, 7, 708-716.	1.5	21

#	ARTICLE	IF	CITATIONS
37	Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling. <i>Cancer Prevention Research</i> , 2014, 7, 1198-1209.	1.5	49
38	Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APCMin/+ mice. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1380-1382.	2.2	3
39	Chemopreventive Effects of the p53-Modulating Agents CP-31398 and Prima-1 in Tobacco Carcinogen-Induced Lung Tumorigenesis in A/J Mice. <i>Neoplasia</i> , 2013, 15, 1018-1027.	5.3	18
40	Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. <i>Translational Oncology</i> , 2013, 6, 649-IN7.	3.7	134
41	Multitargeted Low-Dose GLAD Combination Chemoprevention: A Novel and Promising Approach to Combat Colon Carcinogenesis. <i>Neoplasia</i> , 2013, 15, 481-IN5.	5.3	13
42	p53-stabilizing Agent CP-31398 Prevents Growth and Invasion of Urothelial Cancer of the Bladder in Transgenic UPII-SV40T Mice. <i>Neoplasia</i> , 2013, 15, 966-974.	5.3	25
43	Chemoprevention of Colon and Small Intestinal Tumorigenesis in <i>APCmin/+</i> Mice By SHetA2 (NSC721689) without Toxicity. <i>Cancer Prevention Research</i> , 2013, 6, 908-916.	1.5	27
44	Mass profiling of serum to distinguish mice with pancreatic cancer induced by a transgenic <i>Kras</i> mutation. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	5.1	9
45	Chemopreventive Efficacy of Raloxifene, Bexarotene, and Their Combination on the Progression of Chemically Induced Colon Adenomas to Adenocarcinomas in Rats. <i>Cancer Prevention Research</i> , 2013, 6, 1251-1261.	1.5	15
46	Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. <i>Oncology Reports</i> , 2013, 30, 952-960.	2.6	8
47	Chemopreventive Effects of RXR-Selective Retinoid Bexarotene on Intestinal Neoplasia of <i>ApcMin/+</i> Mice. <i>Neoplasia</i> , 2012, 14, 159-168.	5.3	39
48	Lipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 316-324.	0.5	33
49	Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in <i>p48Cre/+LSL-KrasG12D/+</i> Mice. <i>Neoplasia</i> , 2012, 14, 778-IN1.	5.3	41
50	Endogenous n-3 Polyunsaturated Fatty Acids Delay Progression of Pancreatic Ductal Adenocarcinoma in <i>Fat-1-p48Cre/+LSL-KrasG12D/+</i> Mice. <i>Neoplasia</i> , 2012, 14, 1249-IN46.	5.3	46
51	Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in <i>p48^{Cre/+}LSL-Kras^{G12D/+}</i> mice. <i>International Journal of Cancer</i> , 2012, 131, 1951-1962.	5.1	67
52	Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1301-1306.	2.3	7
53	Chemoprevention of Colon and Small Intestinal Tumorigenesis in <i>APCMin/+</i> Mice by Licofelone, a Novel Dual 5-LOX/COX Inhibitor: Potential Implications for Human Colon Cancer Prevention. <i>Cancer Prevention Research</i> , 2011, 4, 2015-2026.	1.5	56
54	Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 507-523.	5.9	78

#	ARTICLE	IF	CITATIONS
55	DCAMKL-1 Regulates Epithelial-Mesenchymal Transition in Human Pancreatic Cells through a miR-200a-Dependent Mechanism. <i>Cancer Research</i> , 2011, 71, 2328-2338.	0.9	192
56	Chemopreventive Effects of Frondanol A5, a <i>Cucumaria frondosa</i> Extract, against Rat Colon Carcinogenesis and Inhibition of Human Colon Cancer Cell Growth. <i>Cancer Prevention Research</i> , 2010, 3, 82-91.	1.5	44
57	The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. <i>Cancer Prevention Research</i> , 2010, 3, 1417-1426.	1.5	49
58	Î²-Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth, and induces retinoid X receptor-Î± in human colon cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 181-190.	4.1	52